Another study reported that CD133 expression was not a predictive marker in GBM patients and analyses of possible correlation between CD133 expression and MGMT protein expression or MGMT promoter methylation were negative [44], therefore further studies are needed to determine the clinical utility of CD133. Here, PROM1 is linked to glioblastoma.